1
|
Wang K, Zhu K, Zhu Z, Shao F, Qian R, Wang C, Dong H, Li Y, Gao Z, Zhao J. Triptolide with hepatotoxicity and nephrotoxicity used in local delivery treatment of myocardial infarction by thermosensitive hydrogel. J Nanobiotechnology 2023; 21:227. [PMID: 37461079 DOI: 10.1186/s12951-023-01980-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Accepted: 07/03/2023] [Indexed: 07/20/2023] Open
Abstract
Myocardial infarction (MI) resulting from coronary artery occlusion is the leading global cause of cardiovascular disability and mortality. Anti-inflammatory treatment plays an important role in MI treatment. Triptolide (TPL), as a Chinese medicine monomer, has a variety of biological functions, including anti-inflammatory, anti-tumor, and immunoregulation. However, it has been proved that TPL is poorly water soluble, and has clear hepatotoxicity and nephrotoxicity, which seriously limits its clinical application. Herein, we designed a long-acting hydrogel platform (TPL@PLGA@F127) for MI treatment by intramyocardial injection. First, we found that the inflammatory response and immune regulation might be the main mechanisms of TPL against MI by network pharmacology. Subsequently, we prepared the hydrogel platform (TPL@PLGA@F127) and tested its effects and toxicity on normal organs in the early stage of MI (3 days after MI-operation). The results showed that TPL@PLGA@F127 could not only promote "repair" macrophages polarization (to M2 macrophage) by day 3 after MI, but also has a long-lasting anti-inflammatory effect in the later stage of MI (28 days after MI-operation). Additionally, we proved that TPL@PLGA@F127 could attenuate the toxicity of TPL by releasing it more slowly and stably. Finally, we observed the long-term effects of TPL@PLGA@F127 on MI and found that it could improve cardiac function, depress the myocardial fibrosis and protect the cardiomyocytes. In summary, this study indicated that TPL@PLGA@F127 could not only enhance the therapeutic effects of TPL on MI, but also attenuate the hepatotoxicity and nephrotoxicity, which established a strong foundation for the clinical application of TPL for MI.
Collapse
Affiliation(s)
- Kun Wang
- Department of Nuclear Medicine, Shanghai East Hospital, School of medicine, Tongji University, Shanghai, 200120, China
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Hubei Key Laboratory of Molecular Imaging, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China
| | - Ke Zhu
- Department of Nuclear Medicine, The First People's Hospital of Zigong, Zigong, 643099, Sichuan, China
| | - Ziyang Zhu
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Hubei Key Laboratory of Molecular Imaging, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China
| | - Fuqiang Shao
- Department of Nuclear Medicine, The First People's Hospital of Zigong, Zigong, 643099, Sichuan, China
| | - Ruijie Qian
- Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China
| | - Chenyang Wang
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Hubei Key Laboratory of Molecular Imaging, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China
| | - Haiqing Dong
- The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai, 200092, China
| | - Yongyong Li
- The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai, 200092, China
| | - Zairong Gao
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Hubei Key Laboratory of Molecular Imaging, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.
| | - Jun Zhao
- Department of Nuclear Medicine, Shanghai East Hospital, School of medicine, Tongji University, Shanghai, 200120, China.
| |
Collapse
|
2
|
Zhu K, Yao Y, Wang K, Shao F, Zhu Z, Song Y, Zhou Z, Jiang D, Lan X, Qin C. Berberin sustained-release nanoparticles were enriched in infarcted rat myocardium and resolved inflammation. J Nanobiotechnology 2023; 21:33. [PMID: 36709291 PMCID: PMC9883926 DOI: 10.1186/s12951-023-01790-w] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Accepted: 01/20/2023] [Indexed: 01/29/2023] Open
Abstract
Inflammatory regulation induced by macrophage polarization is essential for cardiac repair after myocardial infarction (MI). Berberin (BBR) is an isoquinoline tetrasystemic alkaloid extracted from plants. This study analyzes the most likely mechanism of BBR in MI treatment determined via network pharmacology, showing that BBR acts mainly through inflammatory responses. Because platelets (PLTs) can be enriched in the infarcted myocardium, PLT membrane-coated polylactic-co-glycolic acid (PLGA) nanoparticles (BBR@PLGA@PLT NPs) are used, which show enrichment in the infarcted myocardium to deliver BBR sustainably. Compared with PLGA nanoparticles, BBR@PLGA@PLT NPs are more enriched in the infarcted myocardium and exhibit less uptake in the liver. On day three after MI, BBR@PLGA@PLT NPs administration significantly increases the number of repaired macrophages and decreases the number of inflammatory macrophages and apoptotic cells in infarcted rat myocardium. On the 28th day after MI, the BBR@PLGA@PLT group exhibits a protective effect on cardiac function, reduced cardiac collagen deposition, improved scar tissue stiffness, and an excellent angiogenesis effect. In addition, BBR@PLGA@PLT group has no significant impact on major organs either histologically or enzymologically. In summary, the therapeutic effect of BBR@PLGA@PLT NPs on MI is presented in detail from the perspective of the resolution of inflammation, and a new solution for MI treatment is proposed.
Collapse
Affiliation(s)
- Ke Zhu
- grid.33199.310000 0004 0368 7223Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022 Hubei China ,grid.412839.50000 0004 1771 3250Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022 Hubei China ,Department of Nuclear Medicine, The First People’s Hospital of Zigong, Zigong, Sichuan China
| | - Yu Yao
- grid.33199.310000 0004 0368 7223Department of Ultrasound, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei China
| | - Kun Wang
- grid.33199.310000 0004 0368 7223Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022 Hubei China ,grid.24516.340000000123704535Department of Nuclear Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
| | - Fuqiang Shao
- Department of Nuclear Medicine, The First People’s Hospital of Zigong, Zigong, Sichuan China
| | - Ziyang Zhu
- grid.33199.310000 0004 0368 7223Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022 Hubei China ,grid.412839.50000 0004 1771 3250Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022 Hubei China
| | - Yangmeihui Song
- grid.33199.310000 0004 0368 7223Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022 Hubei China ,grid.412839.50000 0004 1771 3250Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022 Hubei China
| | - Zhangyongxue Zhou
- grid.33199.310000 0004 0368 7223Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022 Hubei China ,grid.412839.50000 0004 1771 3250Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022 Hubei China
| | - Dawei Jiang
- grid.33199.310000 0004 0368 7223Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022 Hubei China ,grid.412839.50000 0004 1771 3250Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022 Hubei China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Biological Targeted Therapy, The Ministry of Education, Wuhan, 430022 Hubei China
| | - Xiaoli Lan
- grid.33199.310000 0004 0368 7223Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022 Hubei China ,grid.412839.50000 0004 1771 3250Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022 Hubei China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Biological Targeted Therapy, The Ministry of Education, Wuhan, 430022 Hubei China
| | - Chunxia Qin
- grid.33199.310000 0004 0368 7223Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022 Hubei China ,grid.412839.50000 0004 1771 3250Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022 Hubei China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Biological Targeted Therapy, The Ministry of Education, Wuhan, 430022 Hubei China
| |
Collapse
|